p53 modulates the exonuclease activity of Werner syndrome protein

被引:78
作者
Brosh, RM
Harmakar, P
Sommers, JA
Yang, Q
Wang, XW
Spillare, EA
Harris, CC
Bohr, VA
机构
[1] NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA
[2] NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 21892 USA
关键词
D O I
10.1074/jbc.M103332200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Werner syndrome (WS) is characterized by the early onset of symptoms of premature aging, cancer, and genomic instability. The molecular basis of the defects is not understood but presumably relates to the DNA helicase and exonuclease activities of the protein encoded by the WRN gene that is mutated in the disease. The attenuation of p53-mediated apoptosis in WS cells and reported physical interaction between WRN and the tumor suppressor p53 suggest that p53 and WRN functionally interact in a pathway necessary for the normal cellular response. In this study, we have demonstrated that p53 inhibits the exonuclease activity of the purified full-length recombinant WRN protein. p53 did not have an effect on a truncated amino-terminal WRN fragment that retains exonuclease activity but lacks the physical interaction domain for p53 located in the carboxyl terminus. Two naturally occurring p53 mutants found in human cancer displayed a reduced ability to inhibit WRN exonuclease activity. In cells arrested in S phase with hydroxyurea, WRN exits the nucleolus and colocalizes with p53 in the nucleoplasm. The regulation of WRN function by p53 is likely to play an important role in the maintenance of genomic integrity and prevention of cancer and other clinical symptoms associated with WS.
引用
收藏
页码:35093 / 35102
页数:10
相关论文
共 50 条
[21]   Characterization of the human and mouse WRN 3′→5′ exonuclease [J].
Huang, SR ;
Beresten, S ;
Li, BM ;
Oshima, J ;
Ellis, NA ;
Campisi, J .
NUCLEIC ACIDS RESEARCH, 2000, 28 (12) :2396-2405
[22]   Werner syndrome protein -: II.: Characterization of the integral 3′→5′-DNA exonuclease [J].
Kamath-Loeb, AS ;
Shen, JC ;
Loeb, LA ;
Fry, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (51) :34145-34150
[23]   A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA [J].
KASTAN, MB ;
ZHAN, QM ;
ELDEIRY, WS ;
CARRIER, F ;
JACKS, T ;
WALSH, WV ;
PLUNKETT, BS ;
VOGELSTEIN, B ;
FORNACE, AJ .
CELL, 1992, 71 (04) :587-597
[24]  
KERN SE, 1991, ONCOGENE, V6, P131
[25]   IDENTIFICATION OF P53 AS A SEQUENCE-SPECIFIC DNA-BINDING PROTEIN [J].
KERN, SE ;
KINZLER, KW ;
BRUSKIN, A ;
JAROSZ, D ;
FRIEDMAN, P ;
PRIVES, C ;
VOGELSTEIN, B .
SCIENCE, 1991, 252 (5013) :1708-1711
[26]   EFFECTS OF THE CELLULAR P53 PROTEIN ON SIMIAN-VIRUS-40-T-ANTIGEN-CATALYZED DNA UNWINDING INVITRO [J].
KIENZLE, H ;
BAACK, M ;
KNIPPERS, R .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1989, 184 (01) :181-186
[27]   CANCER - P53, GUARDIAN OF THE GENOME [J].
LANE, DP .
NATURE, 1992, 358 (6381) :15-16
[28]   The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I [J].
Lebel, M ;
Spillare, EA ;
Harris, CC ;
Leder, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (53) :37795-37799
[29]   p53, the cellular gatekeeper for growth and division [J].
Levine, AJ .
CELL, 1997, 88 (03) :323-331
[30]   Mutations in the WRN gene in mice accelerate mortality in a p53-null background [J].
Lombard, DB ;
Beard, C ;
Johnson, B ;
Marciniak, RA ;
Dausman, J ;
Bronson, R ;
Buhlmann, JE ;
Lipman, R ;
Curry, R ;
Sharpe, A ;
Jaenisch, R ;
Guarente, L .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (09) :3286-3291